Biotech Conference Coverage Day 3 Session 4 - Cartesian Therapeutics, Inc.

RNAC (quick overview): Cartesian’s transient mRNA CAR-T could offer myasthenia gravis patients a finite six-dose, outpatient treatment without lymphodepletion and potentially durable control. The decisive catalyst is the Q1 2027 Phase 3 readout; management reported deep symptom reductions in Phase 2b, but multi-year durability observations were uncontrolled. At $8.34, upside could be attractive if successful, though valuation hinges on clinical replication and adoption of cell therapy in autoimmune disease.

Read full article (2 min)